BR112016004889A2 - derivados de 1,2,4-oxadiazol como imunomoduladores - Google Patents

derivados de 1,2,4-oxadiazol como imunomoduladores

Info

Publication number
BR112016004889A2
BR112016004889A2 BR112016004889A BR112016004889A BR112016004889A2 BR 112016004889 A2 BR112016004889 A2 BR 112016004889A2 BR 112016004889 A BR112016004889 A BR 112016004889A BR 112016004889 A BR112016004889 A BR 112016004889A BR 112016004889 A2 BR112016004889 A2 BR 112016004889A2
Authority
BR
Brazil
Prior art keywords
therapeutic agents
immunomodulators
derivatives
oxadiazole derivatives
relates
Prior art date
Application number
BR112016004889A
Other languages
English (en)
Other versions
BR112016004889B1 (pt
Inventor
Ramachandra Muralidhara
Govindan Nair Sasikumar Pottayil
Setty Sudarshan Naremadde-Palli Seetharamaiah
Original Assignee
Aurigene Discovery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Tech Ltd filed Critical Aurigene Discovery Tech Ltd
Publication of BR112016004889A2 publication Critical patent/BR112016004889A2/pt
Publication of BR112016004889B1 publication Critical patent/BR112016004889B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/08—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and more than one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

a presente invenção se refere a compostos de 1,2,4-oxadiazol e 1,2,4-tiadiazol como agentes terapêuticos com capacidade para inibir a via de sinalização de morte celular programada 1 (pd1). a invenção também se refere a derivados dos agentes terapêuticos. a invenção também abrange o uso dos ditos agentes terapêuticos e 5 derivados para tratamento de distúrbios através de imunopotencialização que compreende a inibição de sinal imunossupressor induzido devido a pd-1, pd-l1, ou pd-l2, e terapias que usam os mesmos.
BR112016004889-0A 2013-09-06 2014-09-05 Derivados de 1,2,4-oxadiazol como imunomoduladores BR112016004889B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN4011CH2013 2013-09-06
IN4011/CHE/2013 2013-09-06
PCT/IB2014/064279 WO2015033299A1 (en) 2013-09-06 2014-09-05 1,2,4-oxadiazole derivatives as immunomodulators

Publications (2)

Publication Number Publication Date
BR112016004889A2 true BR112016004889A2 (pt) 2017-08-01
BR112016004889B1 BR112016004889B1 (pt) 2023-10-03

Family

ID=51830558

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016004889-0A BR112016004889B1 (pt) 2013-09-06 2014-09-05 Derivados de 1,2,4-oxadiazol como imunomoduladores

Country Status (28)

Country Link
US (8) US9233940B2 (pt)
EP (2) EP3041827B1 (pt)
JP (1) JP6521977B2 (pt)
KR (1) KR102362277B1 (pt)
CN (2) CN105814028B (pt)
AU (4) AU2014316682B2 (pt)
BR (1) BR112016004889B1 (pt)
CA (1) CA2922607C (pt)
CU (1) CU24362B1 (pt)
CY (2) CY1120899T1 (pt)
DK (2) DK3041827T3 (pt)
EA (1) EA030155B1 (pt)
ES (2) ES2788848T3 (pt)
HR (2) HRP20181052T1 (pt)
HU (2) HUE048874T2 (pt)
IL (3) IL244314A (pt)
LT (2) LT3363790T (pt)
MX (1) MX365218B (pt)
MY (1) MY186438A (pt)
PH (1) PH12016500406B1 (pt)
PL (2) PL3041827T3 (pt)
PT (2) PT3041827T (pt)
RS (2) RS57508B1 (pt)
SG (1) SG11201601682RA (pt)
SI (2) SI3041827T1 (pt)
TR (1) TR201809838T4 (pt)
WO (1) WO2015033299A1 (pt)
ZA (1) ZA201602193B (pt)

Families Citing this family (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015007051A (es) 2012-12-07 2016-01-12 Chemocentryx Inc Diazol lactamas.
US9687059B2 (en) 2013-08-23 2017-06-27 Preemadonna Inc. Nail decorating apparatus
US11265444B2 (en) 2013-08-23 2022-03-01 Preemadonna Inc. Apparatus for applying coating to nails
HUE039014T2 (hu) * 2013-09-06 2018-12-28 Aurigene Discovery Tech Ltd 1,3,4-Oxadiazol és 1,3,4-tiadiazol származékok, mint immunomodulátorok
TR201809838T4 (tr) * 2013-09-06 2018-07-23 Aurigene Discovery Tech Ltd İmmünomodülatörler olarak 1,2,4-oksadiazol türevleri.
PL3267984T4 (pl) 2015-03-10 2022-05-02 Aurigene Discovery Technologies Limited Związki 1,2,4-oksadiazolu i tiadiazolu jako immunomodulatory
BR112017019304A2 (pt) * 2015-03-10 2018-05-08 Aurigene Discovery Technologies Limited compostos de 1,2,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
MA52119A (fr) 2015-10-19 2018-08-29 Ncyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
JP7148401B2 (ja) 2015-11-19 2022-10-05 インサイト・コーポレイション 免疫調節剤としての複素環化合物
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
SI3394033T1 (sl) 2015-12-22 2021-03-31 Incyte Corporation Heterociklične spojine kot imunomodulatorji
ES2839408T3 (es) 2016-01-13 2021-07-05 Acerta Pharma Bv Combinaciones terapéuticas de un antifolato y un inhibidor de BTK
AU2017246460B2 (en) 2016-04-07 2021-04-22 Chemocentryx, Inc. Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors
US20170320875A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3464279B1 (en) * 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
MX2018016273A (es) 2016-06-20 2019-07-04 Incyte Corp Compuestos heterociclicos como inmunomoduladores.
KR102401963B1 (ko) 2016-06-27 2022-05-25 케모센트릭스, 인크. 면역조절제 화합물
NZ750414A (en) 2016-07-05 2023-02-24 Guangzhou Maxinovel Pharmaceuticals Co Ltd Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
WO2018013789A1 (en) * 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
TWI691494B (zh) 2016-07-28 2020-04-21 瑞士商愛杜西亞製藥有限公司 哌啶衍生物
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018047139A1 (en) * 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
WO2018051254A1 (en) * 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
EP3515453A1 (en) 2016-09-22 2019-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
CA3040143A1 (en) 2016-10-14 2018-04-19 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
CA3040033A1 (en) * 2016-10-20 2018-04-26 Aurigene Discovery Technologies Limited Substituted 1,2,4-oxadiazole compounds as dual inhibitors of vista and pd-1 pathways
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
CN110177552A (zh) * 2016-12-02 2019-08-27 奥古斯塔大学研究所公司 用于调节pd-1信号转导的组合物
HUE060233T2 (hu) * 2016-12-22 2023-02-28 Incyte Corp Tetrahidro imidazo[4,5-c]piridin-származékok mint a PD-L1 internalizációját indukáló szerek
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
BR112019012993A2 (pt) 2016-12-22 2019-12-03 Incyte Corp derivados de benzo-oxazol como imunomoduladores
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
MA47215A (fr) 2017-01-09 2019-11-13 Bioxcel Therapeutics Inc Procédés prédictifs et diagnostiques pour le cancer de la prostate
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11034667B2 (en) 2017-01-09 2021-06-15 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CN108395443B (zh) * 2017-02-04 2021-05-04 广州丹康医药生物有限公司 抑制程序性死亡受体配体1的环状化合物及其用途
CN108794422B (zh) * 2017-04-26 2022-07-01 南京圣和药业股份有限公司 作为pd-l1抑制剂的杂环类化合物
CN108863963B (zh) * 2017-05-08 2022-05-27 南京圣和药物研发有限公司 作为pd-l1抑制剂的杂环类化合物
CA3060597A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Phenyl derivatives as pge2 receptor modulators
AU2018268311B2 (en) 2017-05-18 2022-02-10 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as PGE2 receptor modulators
ES2896476T3 (es) 2017-05-18 2022-02-24 Idorsia Pharmaceuticals Ltd Derivados de pirimidina
EA039630B1 (ru) 2017-05-18 2022-02-18 Идорсия Фармасьютиклз Лтд N-замещенные индольные производные
ES2929309T3 (es) 2017-05-18 2022-11-28 Idorsia Pharmaceuticals Ltd Derivados de benzofurano y benzotiofeno como moduladores del receptor PGE2
CN109096219B (zh) * 2017-06-20 2023-03-21 广州丹康医药生物有限公司 一种新型抗pd-l1化合物、其应用及含其的组合物
WO2019020593A1 (en) 2017-07-25 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF MONOCYTOPOISIS
CN111225896B (zh) 2017-07-28 2024-03-26 凯莫森特里克斯股份有限公司 免疫调节剂化合物
MA49859A (fr) 2017-08-08 2021-04-07 Chemocentryx Inc Immunomodulateurs macrocycliques
EP3668880B1 (en) 2017-08-17 2021-10-06 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
WO2019061324A1 (en) * 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
WO2019070886A1 (en) 2017-10-04 2019-04-11 Preemadonna Inc. SYSTEMS AND METHODS FOR ADAPTIVE NAILS PRINTING AND COLLABORATIVE BEAUTY PLATFORM HOSTING
WO2019073399A1 (en) * 2017-10-11 2019-04-18 Aurigene Discovery Technologies Limited CRYSTALLINE FORMS OF 1,2,4-OXADIAZOLE SUBSTITUTED IN POSITION 3
MX2020004531A (es) * 2017-11-03 2020-08-03 Aurigene Discovery Tech Ltd Inhibidores dobles de tim-3 y las vias de pd-1.
CN111213059B (zh) 2017-11-06 2024-01-09 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
EA202090749A1 (ru) 2017-11-06 2020-08-19 Ориджен Дискавери Текнолоджис Лимитед Способы совместной терапии для иммуномодуляции
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111566120B (zh) 2017-12-20 2023-09-29 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
JP7293560B2 (ja) 2017-12-29 2023-06-20 グアンジョウ マキシノベル ファーマシューティカルズ カンパニー リミテッド 芳香族ビニルまたは芳香族エチル系誘導体、その製造方法、中間体、薬物組成物および使用
CN112004537A (zh) 2018-01-09 2020-11-27 穿梭药业公司 用于治疗人疾病的选择性组蛋白去乙酰化酶抑制剂
ES2933820T3 (es) 2018-01-10 2023-02-14 Idorsia Pharmaceuticals Ltd Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidina-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de la vasculitis y las enfermedades inflamatorias
EP3737401A4 (en) * 2018-01-12 2021-09-15 Aurigene Discovery Technologies Limited 1,2,4-OXADIAZOLE COMPOUNDS AS CD47 SIGNALING PATHWAY INHIBITORS
JP7217279B2 (ja) 2018-01-15 2023-02-02 イドーシア ファーマシューティカルズ リミテッド インドールアミン ２，３－ジオキシゲナーゼ及び／又はトリプトファン ２，３－ジオキシゲナーゼの阻害剤
JP7281470B2 (ja) 2018-01-19 2023-05-25 イドーシア ファーマシューティカルズ リミテッド Ｃ５ａ受容体調節剤
CN111615513A (zh) 2018-01-19 2020-09-01 爱杜西亚药品有限公司 C5a受体调节剂
US11339148B2 (en) 2018-01-26 2022-05-24 Idorsia Pharmaceuticals Ltd. Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
MA51232A (fr) 2018-02-22 2020-10-07 Chemocentryx Inc Indane-amines utiles en tant qu'antagonistes de pd-l1
PL3759109T3 (pl) 2018-02-26 2024-03-04 Gilead Sciences, Inc. Podstawione związki pirolizyny jako inhibitory replikacji hbv
US20210030703A1 (en) 2018-03-12 2021-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
JP7417804B2 (ja) * 2018-03-14 2024-01-19 オーリジーン オンコロジー リミテッド １，２，４－オキサジアゾール化合物を用いてｔｉｇｉｔおよびｐｄ－１のシグナル伝達経路をモジュレートする方法
SI3774791T1 (sl) 2018-03-30 2023-04-28 Incyte Corporation Heterociklične spojine kot imunomodulatorji
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
JP7296398B2 (ja) 2018-04-06 2023-06-22 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ３’３’－環状ジヌクレオチド
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
HUE061503T2 (hu) 2018-05-11 2023-07-28 Incyte Corp Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok
EP3810109A4 (en) 2018-05-31 2022-03-16 Peloton Therapeutics, Inc. COMPOSITIONS AND METHODS FOR INHIBITING CD73
TWI819011B (zh) 2018-06-23 2023-10-21 美商建南德克公司 以pd-1 軸結合拮抗劑、鉑劑及拓撲異構酶ii 抑制劑治療肺癌之方法
WO2020014643A1 (en) 2018-07-13 2020-01-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
JP2021530502A (ja) 2018-07-18 2021-11-11 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト、代謝拮抗剤、及びプラチナ製剤で肺がんを治療する方法
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
TW202024023A (zh) 2018-09-03 2020-07-01 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
WO2020048942A1 (en) 2018-09-04 2020-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
WO2020058372A1 (en) 2018-09-19 2020-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
BR112021003678A2 (pt) 2018-09-20 2021-05-18 Iovance Biotherapeutics, Inc. métodos para criopreservar tecido de tumor, para fabricar, para preparar e para expandir linfócitos infiltrantes de tumor, para tratar um indivíduo com câncer e para tratar câncer para um indivíduo humano, e, fragmento de tumor criopreservado .
WO2020070053A1 (en) 2018-10-01 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inhibitors of stress granule formation for targeting the regulation of immune responses
CN111057069B (zh) * 2018-10-16 2024-01-26 武汉光谷通用名药物研究院有限公司 一种环状化合物、其应用及组合物
CN112955435A (zh) 2018-10-24 2021-06-11 吉利德科学公司 Pd-1/pd-l1抑制剂
MX2021005047A (es) 2018-10-31 2021-09-08 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
KR20210089195A (ko) 2018-11-02 2021-07-15 상하이 맥시노벨 파마수티컬스 씨오., 엘티디. 비페닐계 화합물, 이의 중간체, 제조 방법, 약학 조성물 및 용도
EP3876931A1 (en) 2018-11-08 2021-09-15 Aurigene Discovery Technologies Limited Combination of small molecule cd-47 inhibitors with other anti-cancer agents
EP3887823B1 (en) 2018-11-28 2024-01-17 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and kit for assaying lytic potential of immune effector cells
WO2020115262A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
EP3897624A1 (en) 2018-12-17 2021-10-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of sulconazole as a furin inhibitor
CN113574386A (zh) 2019-01-03 2021-10-29 国家医疗保健研究所 用于增强癌症患者的cd8+t细胞依赖性免疫应答的方法和药物组合物
WO2020150152A1 (en) 2019-01-14 2020-07-23 Genentech, Inc. Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
EP3911670A1 (en) 2019-01-15 2021-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
WO2020169472A2 (en) 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing phenotypic changes in macrophages
DK3934757T3 (da) 2019-03-07 2023-04-17 Inst Of Organic Chemistry And Biochemistry Ascr V V I 2'3'-cykliske dinukleotider og prodrugs deraf
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
CN109824621A (zh) * 2019-03-28 2019-05-31 中国药科大学 噁二唑类和噻二唑类化合物及其制备方法和用途
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020208060A1 (en) 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
WO2020212484A1 (en) 2019-04-17 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
CN114364703A (zh) 2019-04-19 2022-04-15 豪夫迈·罗氏有限公司 抗mertk抗体及它们的使用方法
WO2020225077A1 (en) 2019-05-03 2020-11-12 Idorsia Pharmaceuticals Ltd Pyrimido[4,5-b]indol derivatives as pdhk1 inhibitors
BR112021022659A2 (pt) 2019-05-15 2022-03-29 Chemocentryx Inc Compostos triarílicos para o tratamento de doenças pd-l1
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
JP2022534889A (ja) 2019-05-24 2022-08-04 ファイザー・インコーポレイテッド Ｃｄｋ阻害剤を使用した組合せ療法
MA55325A (fr) 2019-06-20 2022-04-27 Chemocentryx Inc Composés pour le traitement de maladies pd-l1
EP3996682B1 (en) 2019-07-09 2024-02-28 Idorsia Pharmaceuticals Ltd Pharmaceutical composition comprising a tetrahydropyrazolopyrimidinone compound
KR20220034829A (ko) 2019-07-10 2022-03-18 케모센트릭스, 인크. Pd-l1 억제제로서의 인단
WO2021005222A1 (en) 2019-07-11 2021-01-14 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
JP2022544189A (ja) 2019-08-09 2022-10-17 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩
CN111718310B (zh) * 2019-08-19 2021-06-11 中国药科大学 苯基取代的五元杂环类化合物及其制备方法、用途和药物组合物
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
CA3152690A1 (en) 2019-09-30 2021-04-08 Lingyun Wu Compound as small molecule inhibitor pd-1/pd-l1 and application thereof
WO2021067217A1 (en) 2019-09-30 2021-04-08 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
PE20221111A1 (es) 2019-09-30 2022-07-11 Gilead Sciences Inc Vacunas para vhb y metodos de tratamiento de vhb
EP3800201A1 (en) 2019-10-01 2021-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd28h stimulation enhances nk cell killing activities
US20220363776A1 (en) 2019-10-04 2022-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
AU2020368393A1 (en) 2019-10-16 2022-04-21 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
MX2022004450A (es) 2019-10-16 2022-05-03 Chemocentryx Inc Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
BR112022009031A2 (pt) 2019-11-11 2022-10-11 Incyte Corp Sais e formas cristalinas de um inibidor de pd-1/pd-l1
MX2022005775A (es) 2019-11-13 2022-06-09 Genentech Inc Compuestos terapeuticos y metodos de uso.
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
KR20220125278A (ko) 2020-01-03 2022-09-14 상하이 한서 바이오메디컬 컴퍼니 리미티드 비페닐 유도체 억제제, 이의 제조 방법 및 용도
EP4087922A4 (en) 2020-01-07 2024-01-10 Univ Texas HUMAN ADENOSINE/METHYLTHIOADENOSINE DEPLETING ENZYME VARIANTS FOR CANCER TREATMENT
CN115397459A (zh) 2020-01-31 2022-11-25 基因泰克公司 用pd-1轴结合拮抗剂和rna疫苗诱导新表位特异性t细胞的方法
CN115605493A (zh) 2020-03-20 2023-01-13 吉利德科学公司（Us） 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法
CA3176356A1 (en) 2020-04-22 2021-10-28 Anne BROOKS Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
KR20230042222A (ko) 2020-05-26 2023-03-28 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 중증 급성 호흡기 증후군 코로나바이러스 2(sars-cov-2) 폴리펩티드 및 백신 목적을 위한 이의 용도
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
WO2022052926A1 (zh) 2020-09-09 2022-03-17 广州再极医药科技有限公司 芳香乙烯类化合物、其制备方法、中间体、药物组合物及其应用
WO2022086957A1 (en) 2020-10-20 2022-04-28 Genentech, Inc. Peg-conjugated anti-mertk antibodies and methods of use
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
AU2021369590A1 (en) 2020-10-28 2023-06-22 Ikena Oncology, Inc. Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
AR124001A1 (es) 2020-11-06 2023-02-01 Incyte Corp Proceso para fabricar un inhibidor pd-1 / pd-l1 y sales y formas cristalinas del mismo
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
MX2023005570A (es) 2020-11-12 2023-05-29 Inst Nat Sante Rech Med Anticuerpos conjugados o fusionados al dominio de union del receptor de la proteina de la espicula de sars-cov-2 y usos de los mismos con fines de vacunacion.
WO2022101463A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
CA3202523A1 (en) 2020-12-02 2022-06-09 Genentech, Inc. Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy
US20220168293A1 (en) 2020-12-02 2022-06-02 Pfizer Inc. Time to resolution of axitinib-related adverse events
WO2022219080A1 (en) 2021-04-14 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve nk cells cytotoxicity
JP2024516230A (ja) 2021-04-30 2024-04-12 ジェネンテック， インコーポレイテッド がんのための治療及び診断方法並びに組成物
KR20240006683A (ko) 2021-05-13 2024-01-15 길리애드 사이언시즈, 인코포레이티드 TLR8 조절 화합물과 항-HBV siRNA 치료제의 조합물
AU2022291381A1 (en) 2021-06-11 2023-11-30 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
KR20240019330A (ko) 2021-06-11 2024-02-14 길리애드 사이언시즈, 인코포레이티드 Mcl-1 저해제와 항체 약물 접합체의 조합
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222595A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US20230046340A1 (en) 2021-06-23 2023-02-16 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
TW202309078A (zh) 2021-07-02 2023-03-01 美商建南德克公司 治療癌症之方法及組成物
WO2023280790A1 (en) 2021-07-05 2023-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
CA3224180A1 (en) 2021-07-28 2023-02-02 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
WO2023010094A2 (en) 2021-07-28 2023-02-02 Genentech, Inc. Methods and compositions for treating cancer
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
WO2023057548A1 (en) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
TW202325278A (zh) 2021-10-26 2023-07-01 瑞士商愛杜西亞製藥有限公司 Ccr6受體調節劑
WO2023073082A1 (en) 2021-10-28 2023-05-04 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2023088968A1 (en) 2021-11-17 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Universal sarbecovirus vaccines
US20230203062A1 (en) 2021-11-24 2023-06-29 Genentech, Inc. Therapeutic compounds and methods of use
TW202332429A (zh) 2021-11-24 2023-08-16 美商建南德克公司 治療性化合物及其使用方法
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
WO2024015897A1 (en) 2022-07-13 2024-01-18 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020432A1 (en) 2022-07-19 2024-01-25 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
WO2024052356A1 (en) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3227725A (en) 1962-04-17 1966-01-04 Union Carbide Corp Certain 3,5-disubstituted 1,2,4-oxadiazole compounds
TW201311B (pt) 1991-06-17 1993-03-01 Hoffmann La Roche
CA2143246C (en) 1994-03-16 2000-08-22 Thierry Godel Imidazodiazepines
BR0012327A (pt) * 1999-07-09 2002-07-02 Ortho Mcneil Pharm Inc Pirrolidinas e piperidinas neurotróficas, e composições e métodos relacionados
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
BR0208637A (pt) 2001-04-02 2004-12-07 Wyeth Corp Pd-1, um receptor para b7-4, e usos dos mesmos
WO2002086083A2 (en) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
GB0204159D0 (en) 2002-02-22 2002-04-10 British Biotech Pharm Metalloproteinase inhibitors
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
TW200524601A (en) 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
JP5065908B2 (ja) 2004-12-24 2012-11-07 プロシディオン・リミテッド Ｇタンパク質結合受容体作動薬
KR101498834B1 (ko) 2005-05-09 2015-03-05 오노 야꾸힝 고교 가부시키가이샤 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
US20090170907A1 (en) 2005-06-06 2009-07-02 Smithkline Beecham Corporation Chemical Compounds
US20090042926A1 (en) 2005-12-20 2009-02-12 Jason Imbriglio Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
US8748627B2 (en) 2006-02-15 2014-06-10 Abbvie Inc. Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
US20080021026A1 (en) 2006-07-20 2008-01-24 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
CN104341371A (zh) 2006-09-25 2015-02-11 Ptc医疗公司 3-[5-(2-氟苯基)-[1,2,4]噁二唑-3-基]-苯甲酸的晶型
DK2170959T3 (da) 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
AU2008272818A1 (en) 2007-07-02 2009-01-08 Yu, Ming Dr Methods, composition, targets for combinational cancer treatments
US7868001B2 (en) 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
EP2252612B1 (en) 2008-02-22 2012-03-28 Irm Llc Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
US20110275673A1 (en) 2008-09-19 2011-11-10 Yibin Xiang Inhibitors of sphingosine kinase 1
US20120088747A1 (en) 2008-10-30 2012-04-12 Saunders Jeffrey O Sulfonamide containing compounds and uses thereof
TWI686405B (zh) 2008-12-09 2020-03-01 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
KR101790767B1 (ko) 2009-11-24 2017-10-26 메디뮨 리미티드 Ｂ７―ｈ１에 대한 표적화된 결합 물질
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
WO2011137587A1 (en) 2010-05-06 2011-11-10 Hutchison Medipharma Limited Cytokine inhibitors
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012129564A2 (en) 2011-03-24 2012-09-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Proteasome chymotrypsin-like inhibition using pi-1833 analogs
CN103732238A (zh) 2011-06-08 2014-04-16 奥瑞基尼探索技术有限公司 用于免疫调节的治疗性化合物
EP2771337B1 (en) 2011-09-27 2017-08-02 Novartis AG 3-(pyrimidin-4-yl)-oxazolidin-2-ones as inhibitors of mutant idh
WO2013132317A1 (en) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
WO2013144704A1 (en) 2012-03-29 2013-10-03 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds from the bc loop of human pd1
CA3139031A1 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
HUE050797T2 (hu) 2012-10-10 2021-01-28 Sangamo Therapeutics Inc T-sejt módosító vegyületek és alkalmazásaik
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
AU2014205317B2 (en) 2013-01-09 2016-11-24 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
JP6387360B2 (ja) 2013-03-14 2018-09-05 ノバルティス アーゲー 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
WO2014147586A1 (en) 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
TR201809838T4 (tr) * 2013-09-06 2018-07-23 Aurigene Discovery Tech Ltd İmmünomodülatörler olarak 1,2,4-oksadiazol türevleri.
HUE039014T2 (hu) 2013-09-06 2018-12-28 Aurigene Discovery Tech Ltd 1,3,4-Oxadiazol és 1,3,4-tiadiazol származékok, mint immunomodulátorok
HUE060420T2 (hu) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk
US10174012B2 (en) 2014-11-04 2019-01-08 The University Of Kansas LKB1-AMPK activators for therapeutic use in polycystic kidney disease
JP2018507885A (ja) 2015-03-10 2018-03-22 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ 免疫調節剤としての１，３，４−オキサジアゾールおよびチアジアゾール化合物
BR112017019304A2 (pt) 2015-03-10 2018-05-08 Aurigene Discovery Technologies Limited compostos de 1,2,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
PL3267984T4 (pl) 2015-03-10 2022-05-02 Aurigene Discovery Technologies Limited Związki 1,2,4-oksadiazolu i tiadiazolu jako immunomodulatory
WO2018047143A1 (en) 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Vista signaling pathway inhibitory compounds useful as immunomodulators
CA3040033A1 (en) 2016-10-20 2018-04-26 Aurigene Discovery Technologies Limited Substituted 1,2,4-oxadiazole compounds as dual inhibitors of vista and pd-1 pathways
WO2019061324A1 (en) 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
WO2019073399A1 (en) 2017-10-11 2019-04-18 Aurigene Discovery Technologies Limited CRYSTALLINE FORMS OF 1,2,4-OXADIAZOLE SUBSTITUTED IN POSITION 3
MX2020004531A (es) 2017-11-03 2020-08-03 Aurigene Discovery Tech Ltd Inhibidores dobles de tim-3 y las vias de pd-1.
EA202090749A1 (ru) 2017-11-06 2020-08-19 Ориджен Дискавери Текнолоджис Лимитед Способы совместной терапии для иммуномодуляции

Also Published As

Publication number Publication date
SI3041827T1 (sl) 2018-09-28
US10590093B2 (en) 2020-03-17
BR112016004889B1 (pt) 2023-10-03
AU2022241543A1 (en) 2022-10-27
MX365218B (es) 2019-05-27
DK3041827T3 (en) 2018-07-16
DK3363790T3 (da) 2020-04-27
MX2016002969A (es) 2016-10-07
WO2015033299A1 (en) 2015-03-12
KR20160081897A (ko) 2016-07-08
MY186438A (en) 2021-07-22
TR201809838T4 (tr) 2018-07-23
JP2016532710A (ja) 2016-10-20
HRP20200703T1 (hr) 2020-09-04
EP3363790A1 (en) 2018-08-22
IL253651A0 (en) 2017-09-28
CN108164474B (zh) 2022-05-17
US9771338B2 (en) 2017-09-26
IL244314A (en) 2017-09-28
CU20160029A7 (es) 2017-02-02
AU2018271231A1 (en) 2018-12-13
HRP20181052T1 (hr) 2018-09-07
US9233940B2 (en) 2016-01-12
US20230167076A1 (en) 2023-06-01
EP3041827A1 (en) 2016-07-13
CN105814028A (zh) 2016-07-27
CA2922607A1 (en) 2015-03-12
EP3363790B1 (en) 2020-02-19
US11512060B2 (en) 2022-11-29
NZ718711A (en) 2021-10-29
JP6521977B2 (ja) 2019-05-29
LT3363790T (lt) 2020-05-11
AU2020239615A1 (en) 2020-10-15
US20150073042A1 (en) 2015-03-12
PH12016500406A1 (en) 2016-05-16
US20210198219A1 (en) 2021-07-01
IL268035A (en) 2019-09-26
PT3041827T (pt) 2018-07-09
SG11201601682RA (en) 2016-04-28
PH12016500406B1 (en) 2016-05-16
RS60317B1 (sr) 2020-07-31
IL253651B (en) 2019-07-31
ES2675027T3 (es) 2018-07-05
IL244314A0 (en) 2016-04-21
SI3363790T1 (sl) 2020-08-31
US20150073024A1 (en) 2015-03-12
CU24362B1 (es) 2018-10-04
IL268035B (en) 2020-04-30
EA201600236A1 (ru) 2016-08-31
KR102362277B1 (ko) 2022-02-11
PT3363790T (pt) 2020-05-06
EP3041827B1 (en) 2018-04-18
US10173989B2 (en) 2019-01-08
US10961205B2 (en) 2021-03-30
PL3363790T3 (pl) 2020-07-27
HUE048874T2 (hu) 2020-08-28
ES2788848T3 (es) 2020-10-23
ZA201602193B (en) 2022-11-30
CY1120899T1 (el) 2019-12-11
CA2922607C (en) 2022-08-30
CN105814028B (zh) 2018-02-16
LT3041827T (lt) 2018-07-25
CY1122986T1 (el) 2021-10-29
PL3041827T3 (pl) 2018-09-28
EA030155B1 (ru) 2018-06-29
US20200199086A1 (en) 2020-06-25
HUE038169T2 (hu) 2018-09-28
US20180072689A1 (en) 2018-03-15
AU2014316682B2 (en) 2018-11-22
AU2020239615B2 (en) 2022-07-07
US20190144402A1 (en) 2019-05-16
AU2014316682A1 (en) 2016-04-28
AU2018271231B2 (en) 2020-06-25
RS57508B1 (sr) 2018-10-31
US20170101386A1 (en) 2017-04-13
CN108164474A (zh) 2018-06-15

Similar Documents

Publication Publication Date Title
BR112016004889A2 (pt) derivados de 1,2,4-oxadiazol como imunomoduladores
CU20160028A7 (es) Derivados de 1,3,4-oxadiazol y 1,3,4-tiadiazol como inmunomoduladores
BR112017019304A2 (pt) compostos de 1,2,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
BR112017019307A2 (pt) compostos de 1,3,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
BR112017019306A2 (pt) compostos de 1,3,4-oxadiazol e tiadiazol como imunomoduladores
BR112017019303A2 (pt) compostos de 1,2,4-oxadiazol e tiadiazol como imunomoduladores
CU20160027A7 (es) Compuestos peptidomiméticos cíclicos
BR112017019305A2 (pt) compostos cíclicos terapêuticos como imunomoduladores
WO2013132317A8 (en) Peptidomimetic compounds as immunomodulators
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112016007467A2 (pt) compostos heterocíclicos e usos dos mesmos
MX2014011353A (es) Inmunomodulacion de compuestos ciclicos del bucle bc de muerte celular programada (pd1) humana.
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
BR112015028235A2 (pt) (ciano-dimetil-metil)-isoxazóis e -[1,3,4]tiadiazóis
EA202090087A2 (ru) 1,2,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
BR112015023016A2 (pt) derivados de oxindolo carregando um substituinte oxetano e uso do mesmo para tratamento de doenças relacionadas a vasopressina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFIQUE-SE PARA CORRECAO DO QUADRO 1

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/09/2014, OBSERVADAS AS CONDICOES LEGAIS